Establishment Labs Reports Narrowed Losses and FDA Approval

Establishment Labs Holdings ( (ESTA) ) has released its Q3 earnings. Here is a breakdown of the information Establishment Labs Holdings presented to its investors.

Establishment Labs Holdings Inc. is a global medical technology company specializing in breast aesthetics and reconstruction, with a focus on improving women’s health and wellness through innovative solutions like its Motiva® devices. In its third-quarter 2024 financial results, Establishment Labs reported worldwide revenue of $40.2 million and a narrowed loss from operations of $13.1 million, compared to a $21.0 million loss in the same period last year. The company also highlighted a reduction in its adjusted EBITDA loss to $7.0 million, down from $16.3 million in the prior year, signaling improved financial efficiency.

Key financial metrics revealed a decrease in operating expenses by $8.2 million from the previous year, reflecting cost reduction initiatives, while R&D expenses also saw a decrease due to lower personnel costs. Despite a net loss of $16.7 million, the company’s cash position was bolstered to a pro forma balance of $114.0 million, thanks to strategic financial maneuvers including a $50 million direct offering and a credit facility extension.

Strategically, the company celebrated the U.S. launch of its Motiva implants, which received FDA approval, and reported a robust onboarding of new accounts. Additionally, the company anticipates U.S. revenue to exceed $35 million in 2025, as it continues to expand its market presence and sales force in the region.

Looking ahead, Establishment Labs aims to leverage its strengthened financial position and operational efficiencies to pursue global market leadership, with management expressing confidence in sustaining significant revenue growth and emerging profitability in the years to come.